Mundipharma Of Japan To Develop, Market Cancer Drug
This article was originally published in PharmAsia News
Japan's Mundipharma, which normally licenses its drug development and marketing to other drug makers, plans to do develop another company's drug. BioCryst Pharmaceuticals' forodesine HCL compound for treating T-cell lymphoma received orphan status from Japan's Health Ministry and Mundipharma licensed the drug. The Japanese firm expects to begin trials this fall and establish a sales division to market the drug in Japan and Europe on its own. Other drug makers, including Purdue Pharma of the United States, are associated with Mundipharma in the venture. (Click here for more - a subscription may be required
You may also be interested in...
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.